News Website

Patient Safety Network Papers Restored Amid Lawsuit From Doctors - MSN

Patient Safety Network Papers Restored Amid Lawsuit From Doctors MSN

Published: June 18, 2025, 6:06 p.m.

Read Full Article

1st patient dosed in trial of Enhertu for HER2 endometrial cancer - Rare Cancer News

1st patient dosed in trial of Enhertu for HER2 endometrial cancer Rare Cancer News

Published: June 18, 2025, 4:01 p.m.

Read Full Article

Patient Safety Network Papers Restored Amid Lawsuit From Doctors - MedPage Today

Patient Safety Network Papers Restored Amid Lawsuit From Doctors MedPage Today

Published: June 17, 2025, 8:38 p.m.

Read Full Article

Research, patient advocacy aim to fill the gaps in women’s health - The Arkansas Democrat-Gazette

Research, patient advocacy aim to fill the gaps in women’s health The Arkansas Democrat-Gazette

Published: June 15, 2025, 7:34 a.m.

Read Full Article

Physicians, researchers and patients work to improve women’s health - Northwest Arkansas Democrat-Gazette

Physicians, researchers and patients work to improve women’s health Northwest Arkansas Democrat-Gazette

Published: June 15, 2025, 6:05 a.m.

Read Full Article

Endometriosis Patients Say Cannabis Is More Effective Than Rx Medications - NORML

Endometriosis Patients Say Cannabis Is More Effective Than Rx Medications NORML

Published: June 12, 2025, 4:02 p.m.

Read Full Article

WATCH: Cancer patient appeals for assistance - heraldonline.co.zw

WATCH: Cancer patient appeals for assistance heraldonline.co.zw

Published: June 11, 2025, 10:07 a.m.

Read Full Article

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace

Published: June 9, 2025, 12:43 p.m.

Read Full Article

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:18 p.m.

Read Full Article

The impact of GnRH agonists on endometrial immune cells in patients with adenomyosis: a prospective cohort study - BMC Medicine

The impact of GnRH agonists on endometrial immune cells in patients with adenomyosis: a prospective cohort study BMC Medicine

Published: June 8, 2025, 11:34 p.m.

Read Full Article

Latest Articles

Patient Safety Network Papers Restored Amid Lawsuit From Doctors - MSN

1st patient dosed in trial of Enhertu for HER2 endometrial cancer - Rare Cancer News

Patient Safety Network Papers Restored Amid Lawsuit From Doctors - MedPage Today

Research, patient advocacy aim to fill the gaps in women’s health - The Arkansas Democrat-Gazette

Physicians, researchers and patients work to improve women’s health - Northwest Arkansas Democrat-Gazette

Endometriosis Patients Say Cannabis Is More Effective Than Rx Medications - NORML

WATCH: Cancer patient appeals for assistance - heraldonline.co.zw

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

The impact of GnRH agonists on endometrial immune cells in patients with adenomyosis: a prospective cohort study - BMC Medicine

Subscribe to Our Newsletter